Article Details
Retrieved on: 2022-05-06 13:24:01
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
SVB Leerink currently has a “Outperform” rating and a $70.00 target price on the stock. SVB Leerink also issued estimates for AstraZeneca's Q3 2022 ...
Article found on: www.defenseworld.net
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here